TEVA at 36!? Are you kidding me!....this company makes 80% of their revenues from generics! Deals in 32 currencies around the world, has industry leading world wide manufacturing, first to file on many near patent expiry drugs, and has spent… More
TEVA is a "defensive" stock. not something that will boost your portfolio when the market goes bull.people think its Generics, but 30% from TEVA's income is from ethics products - copaxone (for MS) and expose to generics competition. no biogenerics… More